For example, mutations Leu607Ile, Arg698Trp, and Arg621Cys identified in breast cancer patients were shown to have impaired pro-apoptotic function of Rb1 and they stimulated resistance to 5-FU/mitomycin or doxorubicin [72]. Here, RB1 is linked to breast carcinoma.